Eravacycline Proves Non-Inferior to Meropenem for the Treatment of cIAI in IGNITE4 Trial
May 4th 2018Data from the IGNITE4 phase 3 trial supports the use of eravacycline for the treatment of complicated intra-abdominal infections (cIAI), including infections caused by pathogens resistant to other antibiotics.
FDA Advisory Committee Votes Unanimously in Favor of Plazomicin for Adults with cUTIs
May 3rd 2018However, the FDA's Drug Advisory Committee did not feel that there was substantial evidence regarding the safety and effectiveness of plazomicin for the treatment of bloodstream infections in patients with limited or no treatment options.
Trogarzo Now Available In the United States for Those With Multidrug-Resistant HIV
April 30th 2018The US Food and Drug Administration (FDA) approved this new intravenously-administered HIV medication for patients who are suffering from multidrug-resistant HIV who have failed other antiretroviral therapies.
Novartis to Invest $100 Million in Malaria Treatment Research
April 30th 2018The pharmaceutical giant will also launch a program committed to equitable pricing in malaria-endemic countries for new treatments along with expanding pediatric treatment availability and work to strengthen health care systems in 4 African nations.
Risk of Adverse Pregnancy Outcomes with TDF-FTC-ATV/r Similar or Lower Than Other ART Regimens
April 26th 2018A recent study finds no difference in risk for adverse birth outcomes between 3 antiretroviral regimens taken by pregnant women with HIV, including TDF-FTC-LPV/r, a regimen that has raised safety concerns in a past trial.
New Findings on Zika in Semen May Change Recommendations on Preventing Sexual Transmission
April 26th 2018A recent study sheds light on how long Zika virus can be transmitted through semen following infection, while another study assessed the side effects of Zika infection on infants with post-natal exposure.